NSE ScannerMedical Devices & Supplies · Medical Specialties · NSE: QLINE · data 2026-10-31
Q-Line Biotech Limited
In plain words
Price: 30.2% below its 52-week high of ₹735.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | — |
| Net profit (last 12 months) | — |
| Sales growth, 3 years (yearly) | 23.2% |
| Profit growth, 3 years (yearly) | 20.2% |
At a glance
ROE 25.6%, ROCE 27.9%: how much profit it earns on the money it uses.
Debt/equity 0.92, Profit growth 20.2% and sales growth 23.2% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- High return on equity (25.6%).
- Profit grew 20.2% a year over 3 years.
None flagged by these rules.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Smart-money activity
5/100 · Weak over the last ~60 sessions
- Delivery vs usual 0/30: No stored daily delivery history for this stock (0 points).
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Common questions
Is Q-Line Biotech Limited debt-free?
Its latest reported debt-to-equity ratio is 0.92.
What is the 52-week high and low of Q-Line Biotech Limited?
The 52-week high is ₹735 and the 52-week low is ₹431.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Q-Line Biotech Limited | ₹512.75 | ₹1,196 cr | — | — | 25.6% | 27.9% | 0.92 | +13.4% |
| Sahajanand Medical Technologies Limited | ₹462.7 | ₹4,675 cr | — | — | — | — | — | +24.7% |
| Virtuoso Optoelectronics Limited | ₹460.2 | ₹1,575 cr | 83.5 | — | 4.3% | -3.5% | 0.84 | +2.3% |
| MIC Electronics Limited | ₹35.41 | ₹1,057 cr | — | — | -5.8% | 9.4% | 0.2 | -35.6% |
| Osel Devices Limited | ₹335.5 | ₹541 cr | 29 | — | 19.6% | 34.3% | 0.49 | -45.3% |
| Yash Optics and Lens Limited | ₹118.05 | ₹292 cr | 32.3 | 2.9 | 9.5% | 11.6% | 0.05 | -9.2% |
Compare QLINE with SMT in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open QLINE in NSE Scanner →